Neogen
Valuation each multiple against its own 5-year range
Vs. peers Medical Devices
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Neogen (NEOG) | 2.30B | -40.58 | 1.10 | 0.00% |
| Abbott Laboratories (ABT) | 178.39B | 38.29 | 3.50 | 2.41% |
| Medtronic (MDT) | 127.84B | 24.62 | 2.54 | 2.85% |
| Stryker Corp (SYK) | 118.01B | 33.01 | 5.03 | 1.14% |
| Boston Scientific (BSX) | 60.85B | 17.71 | 2.37 | 0.00% |
| Edwards Lifesciences (EW) | 58.56B | 57.54 | 5.39 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 13.0% below Morningstar's fair value estimate.
Fair value
Neogen Corp receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 6% discount to our quantitative fair value estimate of $11.92 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The firm's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 81.3% sits in the top 40% globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.
On a different note, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 3.1%, a core component of profitability, falls in the bottom 45% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.
Economic moat
The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Neogen discussion 0 comments